Toronto Dominion Bank Has $19.78 Million Stock Holdings in Axon Enterprise, Inc. (NASDAQ:AXON)

Toronto Dominion Bank lifted its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 38.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 33,273 shares of the biotechnology company's stock after buying an additional 9,209 shares during the period. Toronto Dominion Bank's holdings in Axon Enterprise were worth $19,775,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Scientech Research LLC raised its stake in Axon Enterprise by 152.6% during the fourth quarter. Scientech Research LLC now owns 2,006 shares of the biotechnology company's stock worth $1,192,000 after acquiring an additional 1,212 shares in the last quarter. Siemens Fonds Invest GmbH grew its holdings in shares of Axon Enterprise by 219.7% during the 4th quarter. Siemens Fonds Invest GmbH now owns 2,481 shares of the biotechnology company's stock valued at $1,475,000 after purchasing an additional 1,705 shares during the last quarter. Skye Global Management LP acquired a new position in Axon Enterprise during the 4th quarter worth approximately $1,902,000. Shell Asset Management Co. increased its position in Axon Enterprise by 7.5% during the 4th quarter. Shell Asset Management Co. now owns 2,449 shares of the biotechnology company's stock worth $1,455,000 after purchasing an additional 170 shares in the last quarter. Finally, Rafferty Asset Management LLC lifted its stake in Axon Enterprise by 74.7% in the 4th quarter. Rafferty Asset Management LLC now owns 36,839 shares of the biotechnology company's stock valued at $21,894,000 after purchasing an additional 15,747 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors.

Axon Enterprise Stock Performance

Shares of Axon Enterprise stock opened at $742.32 on Tuesday. The business has a 50-day moving average price of $588.30 and a two-hundred day moving average price of $597.92. Axon Enterprise, Inc. has a 1-year low of $273.52 and a 1-year high of $742.34. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32. The company has a market cap of $57.79 billion, a P/E ratio of 191.81, a PEG ratio of 5.17 and a beta of 1.24.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. The business had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The firm's revenue for the quarter was up 31.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.15 earnings per share. As a group, analysts anticipate that Axon Enterprise, Inc. will post 5.8 EPS for the current year.

Insider Buying and Selling

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $540.99, for a total value of $5,409,900.00. Following the transaction, the chief executive officer now owns 3,063,982 shares in the company, valued at approximately $1,657,583,622.18. This represents a 0.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeri Williams sold 307 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $552.72, for a total value of $169,685.04. Following the completion of the sale, the director now directly owns 1,627 shares of the company's stock, valued at $899,275.44. This trade represents a 15.87% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 23,764 shares of company stock valued at $14,856,635 over the last ninety days. 4.40% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Craig Hallum downgraded shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a report on Monday, March 10th. Needham & Company LLC boosted their price objective on Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Northcoast Research downgraded Axon Enterprise from a "buy" rating to a "neutral" rating in a research report on Wednesday, February 19th. JMP Securities reissued an "outperform" rating on shares of Axon Enterprise in a research note on Tuesday, February 4th. Finally, The Goldman Sachs Group upped their price objective on Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a research note on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, Axon Enterprise currently has an average rating of "Moderate Buy" and a consensus price target of $652.73.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.